ReviewCurrent pharmaceutical design2025
Therapeutic Potential of Neutralizing Monoclonal Antibodies (nMAbs) against SARS-CoV-2 Omicron Variant.
Pijus Parua et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
4 papers cite it
this papercites it